

PRESS CLIPPING SHEET

PUBLICATION:	Business Today
DATE:	February-2019
COUNTRY:	Egypt
CIRCULATION:	10,000
TITLE :	Announcing the Results of the MONALEESA-7 Advanced Breast Cancer Treatment Trials.
PAGE:	81
ARTICLE TYPE:	Agency-Generated News
REPORTER:	Staff Report
AVE:	1,500

PRESS CLIPPING SHEET

Announcing the Results of the MONALEESA-7 Advanced Breast Cancer Treatment Trials

Novartis Pharma held a news conference, on the sidelines of the 11th Breast Gynecological International Cancer Conference (BGICC), to announce the results of the MONALEESA-7 trials. The study is the first of its kind targeting women suffering from premenopausal or perimenopausal advanced breast cancer and sought to evaluate the effectiveness and safety of "Ribociclib" in the treatment of the disease.

The Egyptian Ministry of Health has approved the drug and permitted its use for patients under the age of 45 who, according to research, represent the most productive segment of society. The trial's impressive results offer oncologists and advanced breast cancer patients a new treatment option. It is of particular value to pre- and perimenopausal women, ensuring that their treatment choices are no longer limited to hormonal and chemotherapy only.

Novartis Oncology General Manager for Egypt, Libya, Tunisia and Morocco, Dr. Sherif Amin, said, "The Company's vision, and its commitment towards patients and healthcare providers, means exerting tireless efforts on scientific research and developing drugs and optimizing treatment options for cancer patients. The record approval and registration speed for this new drug and the permission of its use for this young age bracket—the most productive in the society—suffering from advanced breast cancer represent a significant achievement, and we would like to thank the concerned authorities at the Ministry of Health and the Drug Registration Department for their continued cooperation."